ethyl-paraben potassium | 36457-19-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-paraben potassium
• 英文别名: Potassium ethyl 4-oxidobenzoate；potassium;4-ethoxycarbonylphenolate
• CAS: 36457-19-9
• 化学式: C₉H₉O₃*K
• 分子量: 204.267
• InChiKey: HFTYFFXNUVBSII-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.06
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  过氧化氢酶 、 氯甲酸苯酯 在 三乙胺 作用下， 以 乙醚 、 乙醇 为溶剂， 生成 ethyl-paraben potassium 、 乙基苯基碳酸脂
  参考文献：
  名称：

  苯基Y-取代苯基碳酸酯与碱金属乙醇盐的亲核置换反应动力学研究：金属离子效应和反应机理

  摘要：

  已经测量了苯基 Y 取代苯基碳酸酯与碱金属乙醇盐（EtOM，M = Li、Na 和 K）反应的伪一级速率常数 (kobsd)。kobsd vs. [Et...

  DOI：

  10.1246/bcsj.20120104

文献信息

• Kinetics and Mechanism of Nucleophilic Displacement Reactions of Y-Substituted Phenyl Benzoates with Cyanide Ion
  作者：Song-I Kim、Eun-Hee Kim、Ik-Hwan Um

  DOI：10.5012/bkcs.2010.31.03.689

  日期：2010.3.20

  Discussion The kinetic study was performed spectrophotometrically. All reactions proceeded with quantitative liberation of Y-substituted phenoxide ion (and/or its conjugate acid) under pseudo-first- order conditions (i.e., the nucleophile concentration in excess over the substrate concentration). The reactions obeyed first- order kinetics and pseudo-first-order rate constants (

  Y 取代苯甲酸苯酯 (1) 和苯硫代苯甲酸苯酯 (2) 与 CN 反应的二级速率常数汇总 - 在 80 mol % H 2 O/20 mol % DMSO 中，温度为 25.0 ± 0.1 o C a entry Y p K a 10 2 k CN- / M –1 s –1 12a 4-MeO 10.20 0.843 b 2.13 b 4-Me 10.19 0.783 b 1.89 c 3-CH 3 10.08 0.724 - d H 9.95 1.02 b 2.75 e 4-Cl 9.38 2.32 - f 3-COMe 9.19 3.59 b - g 3-Cl 9.02 4.19 - h 3-CHO 8.98 3.93 - i 4-COOEt 8.50 6.07 - j 3-NO 2 8.35 14.1 b 18.0 k 4-COMe 8.05 7.68 b 7.88 l 4-CN 7
• [EN] GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY<br/>[FR] PEPTIDES DE LA SUPERFAMILLE DU GLUCAGON PRÉSENTANT UNE ACTION SUR LES RÉCEPTEURS AUX GLUCOCORTICOÏDES
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2013074910A1

  公开（公告）日：2013-05-23

  Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.

  本文提供了与GR配体结合的葡萄糖素超家族肽，这些肽能够作用于糖皮质激素受体。本文还提供了该发明的结合物的药物组合物和工具包。此外，本文还提供了治疗疾病的方法，例如代谢紊乱，如糖尿病和肥胖，包括给予该发明的结合物。
• Glucagon/glp-1 receptor co-agonists
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2676673A2

  公开（公告）日：2013-12-25

  Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

  已公开的修饰胰高血糖素肽在胰高血糖素受体上的效力比原生胰高血糖素更强。通过形成分子内桥或用酰胺基团取代末端羧酸来进一步修饰胰高血糖素肽，可产生具有胰高血糖素/GLP-1 受体共激动剂活性的肽。这些高活性胰高血糖素类似物的溶解性和稳定性可通过对多肽进行聚乙二醇化、酰化、烷基化、羧基末端氨基酸的取代、C-末端截断或添加选自 SEQ ID NO: 26 (GPSSGAPPPS)、SEQ ID NO: 27 (KRNRNNIA) 和 SEQ ID NO: 28 (KRNR)的羧基末端肽来进一步改善。
• Inhibitors of beta integrin-G protein alpha subunit binding interactions
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US10011634B2

  公开（公告）日：2018-07-03

  Provided herein are compounds that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

  本文提供了抑制β整合素与G蛋白亚基之间结合相互作用的化合物，以及包含这些化合物的组合物（如药物组合物）和相关试剂盒。在某些实施方案中，化合物是抗体或抗体类似物，而在其他实施方案中，化合物是肽或肽类似物。还提供了使用化合物的方法，包括治疗或预防中风、心脏病、癌症或炎症等病症的方法。
• Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
  申请人：THE UNIVERSITY OF CHICAGO

  公开号：US10017765B2

  公开（公告）日：2018-07-10

  The disclosure provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.

  本公开提供了治疗受试者多聚谷氨酰胺疾病（如脊髓小脑共济失调6型）的方法，包括向受试者施用有效量的IRES抑制剂以治疗受试者的SCA6。本文还提供了IRES抑制剂和包含IRES抑制剂的药物组合物。